|
Federal
Register Notices > Notice
of Application >
Cerilliant Corporation
FR Doc E7-16937 [Federal Register: August 28, 2007 (Volume 72, Number 166)]
[Notices] [Page 49315-49316] From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr28au07-140]
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application
Pursuant to Sec. 1301.33(a) of Title 21 of the Code of Federal Regulations
(CFR),
this is notice that on July 20, 2007, Cerilliant Corporation, 811 Paloma Drive,
Suite A, Round Rock, Texas 78664, made application by renewal to the Drug
Enforcement Administration (DEA) for registration as a bulk manufacturer of the
basic classes of controlled substances listed in schedule I and II:
|
Drug
|
Schedule
|
|
Cathinone (1235)
|
I
|
|
Methcathinone (1237)
|
I
|
|
N-Ethylamphetamine (1475)
|
I
|
|
N,N-Dimethylamphetamine (1480)
|
I
|
|
Aminorex (1585)
|
I
|
|
4-Methylaminorex (cis isomer) (1590)
|
I
|
|
Gamma Hydroxybutyric acid (2010)
|
I
|
|
Methaqualone (2565)
|
I
|
|
Alpha-Ethyltryptamine (7249)
|
I
|
|
Lysergic acid diethylamide (7315)
|
I
|
|
Marihuana (7360)
|
I
|
|
Tetrahydrocannabinols (7370)
|
I
|
|
Mescaline (7381)
|
I
|
|
3,4,5-Trimethoxyamphetamine (7390)
|
I
|
|
4-Bromo-2,5-dimethoxyamphetamine (7391)
|
I
|
|
4-Bromo-2,5-dimethoxyphenethylamine (7392)
|
I
|
|
4-Methyl-2,5-dimethoxyamphetamine (7395)
|
I
|
|
2,5-Dimethoxyamphetamine (7396)
|
I
|
|
2,5-Dimethoxy-4-ethylamphetamine (7399)
|
I
|
|
3,4-Methylenedioxyamphetamine (7400)
|
I
|
|
5-Methoxy-3,4-methylenedioxyamphetamine (7401)
|
I
|
|
N-Hydroxy-3,4-methylendioxyamphetamine (7402)
|
I
|
|
3,4-Methylendioxy-N-ethylamphetamine (7404)
|
I
|
|
3,4-Methylenedioxymethamphetamine (7405)
|
I
|
|
4-Methoxyamphetamine (7411)
|
I
|
|
Alpha-methyltryptamine (7432)
|
I
|
|
Bufotenine (7433)
|
I
|
|
Diethyltryptamine (7434)
|
I
|
|
Dimethyltryptamine (7435)
|
I
|
|
Psilocybin (7437)
|
I
|
|
Psilocyn (7438)
|
I
|
|
Acetyldihydrocodeine (9051)
|
I
|
|
Benzylmorphine (9052)
|
I
|
|
Codeine-N-oxide (9053)
|
I
|
|
Dihydromorphine (9145)
|
I
|
|
Heroin (9200)
|
I
|
|
Hydromorphinol (9301)
|
I
|
|
Methyldihydromorphine (9304)
|
I
|
|
Morphine-N-oxide (9307)
|
I
|
|
Normorphine (9313)
|
I
|
|
Pholcodine (9314)
|
I
|
|
Acetylmethadol (9601)
|
I
|
|
Allylprodine (9602)
|
I
|
|
Alphacetylmethadol except levo-alphacetylmethadol (9603)
|
I
|
|
Alphameprodine (9604)
|
I
|
|
Alphamethadol (9605)
|
I
|
|
Betacetylmethadol (9607)
|
I
|
|
Betameprodine (9608)
|
I
|
|
Betamethadol (9609)
|
I
|
|
Betaprodine (9611)
|
I
|
|
Hydroxypethidine (9627)
|
I
|
|
Noracymethadol (9633)
|
I
|
|
Norlevorphanol (9634)
|
I
|
|
Normethadone (9635)
|
I
|
|
Trimeperidine (9646)
|
I
|
|
Phenomorphan (9647)
|
I
|
|
Para-Fluorofentanyl (9812)
|
I
|
|
3-Methylfentanyl (9813)
|
I
|
|
Alpha-Methylfentanyl (9814)
|
I
|
|
Acetyl-alpha-methylfentanyl (9815)
|
I
|
|
Beta-hydroxyfentanyl (9830)
|
I
|
|
Beta-hydroxy-3-methylfentanyl (9831)
|
I
|
|
Alpha-Methylthiofentanyl (9832)
|
I
|
|
3-Methylthiofentanyl (9833)
|
I
|
|
Thiofentanyl (9835)
|
I
|
|
Amphetamine (1100)
|
II
|
|
Methamphetamine (1105)
|
II
|
|
Phenmetrazine (1631)
|
II
|
|
Methylphenidate (1724)
|
II
|
|
Ambobarbital (2125)
|
II
|
|
Pentobarbital (2270)
|
II
|
|
Secobarbital (2315)
|
II
|
|
Glutethimide (2550)
|
II
|
|
Nabilone (7379)
|
II
|
|
1-Phenylcyclohexylamine (7460)
|
II
|
|
Phencyclidine (7471)
|
II
|
|
1-Piperidinocyclohexane carbonitrile (8603)
|
II
|
|
Alphaprodine (9010)
|
II
|
|
Cocaine (9041)
|
II
|
|
Codeine (9050)
|
II
|
|
Dihydrocodeine (9120)
|
II
|
|
Oxycodone (9143)
|
II
|
|
Hydromorphone (9150)
|
II
|
|
Diphenoxylate (9170)
|
II
|
|
Benzoylecgonine (9180)
|
II
|
|
Ethylmorphine (9190)
|
II
|
|
Hydrocodone (9193)
|
II
|
|
Levomethorphan (9210)
|
II
|
|
Levorphanol (9220)
|
II
|
|
Isomethadone (9226)
|
II
|
|
Meperidine (9230)
|
II
|
|
Methadone (9250)
|
II
|
|
Methadone intermediate (9254)
|
II
|
|
Dextropropoxyphene, bulk (non-dosage forms)(9273)
|
II
|
|
Morphine (9300)
|
II
|
|
Thebaine (9333)
|
II
|
|
Levo-alphacetylmethadol (9648)
|
II
|
|
Oxymorphone (9652)
|
II
|
|
Noroxymorphone (9668)
|
II
|
|
Racemethorphan (9732)
|
II
|
|
Alfentanil (9737)
|
II
|
|
Sufentanil (9740)
|
II
|
|
Fentanyl (9801)
|
II
|
The company plans to manufacture small quantities of the listed controlled
substances to make reference standards which will be distributed to their
customers.
Any other such applicant and any person who is presently registered with DEA
to manufacture such substances may file comments or objections to the issuance
of the proposed registration pursuant to 21 CFR 1301.33(a).
Any such comments or objections being sent via regular mail should be
addressed, in quintuplicate, to the Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative (ODL), Washington, DC 20537;
or any being sent via express mail should be sent to Drug Enforcement
Administration, Office of Diversion Control, Federal Register Representative (ODL),
2401 Jefferson-Davis Highway, Alexandria, Virginia 22301; and must be filed no
later than October 29, 2007.
Dated: August 16, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion
Control, Drug Enforcement Administration.
[FR Doc. E7-16937 Filed 8-27-07; 8:45 am]
BILLING CODE 4410-09-P
NOTICE: This is an
unofficial version. An official version of these publications may be obtained
directly from the Government Printing Office (GPO).
|
